This report was recently updated on November 16 2024 with the latest and most recent
market numbers
Global Male Sexual Therapeutics Market Size, Trends & Analysis - Forecasts to 2026 By Type of Therapeutics (Male Hypogonadism Therapy, Prostate Cancer Therapy, Erectile Dysfunction Therapy, Premature Ejaculation Therapy and Others), Product Type (Capsules, Hormone Injections, and Creams & Ointments), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Competitive Landscape Company Market Share Analysis, and Competitor Analysis
Male sexual health is defined as the state of goodness and well-being that lets a man fully participate in sexual activity with no biological complications. Parameters like psychological, physical, social factors, and interpersonal aspects influence a man's sexual wellbeing. Appropriate male sexual health consists of sexual desire and biological functioning erection. However, many parameters can affect the male sexual wellbeing and affect the biological functioning associated with sexual organs. Some of which are male hypogonadism, prostate cancer, erectile dysfunction, premature ejaculation, and complications associated with testosterone. Men with sexual disorders experience issues related to ejaculation, delayed ejaculation, premature ejaculation, and lack of ability to experience orgasm during ejaculation/anorgasmia. Amongst these, erectile dysfunction is the most affected sexual disorder amongst men. Erectile dysfunction can be described as the lack of or the inability to get an erection during sexual activity. This can be attributed to increased stress levels, damage from urological surgery, relationship issues, depression, hereditary, low testosterone, and cholesterol-clogged arterial issues. As per the data provided by World Health Organization (WHO), as of 2019, more than 52% of male patients will experience some form of erectile dysfunction in their entire life, and as of 2020, the US is home for around 5-15% of ED cases of men whose age is between 40 to 70. This also concludes that the growing geriatric male population may face ED issues in their lifetime. Hence, with the rising male elderly population and associated sexual disorders, the market for male sexual therapeutics will be growing tremendously fast during the forecast period. In addition, another major sexual disorder amongst the male patient population is Hypogonadism. This is the condition in which the male body doesn't produce enough testosterone hormone which plays a vital role in sperm development, male sexual organ development, and other aspects of masculinity. As per WHO, every year in the United States, Hypogonadism affects 4-5 million men. This condition mostly affects and males who fall in the age group of 40-60 years. The statistics also state that more than 60 percent of men above the age of 65 have low testosterone levels. Some of the other factors besides the rising aging population that contribute to male sexual disorders are unhealthy and stressful lifestyle, post-surgical complications, and other psychological aspects. With the rise in these disorders, the therapeutics market is ought to gain traction and growth during the forecast period. In addition, increasing organic growth strategies for launching drugs and medicines that deal with male sexual disorders will help the market grow rapidly in both developed and developing nations. However, lack of knowledge related to male sexual disorders in developing nations may hamper or hinder the growth of the market during the forecast period.
Based on the type of therapeutics for male sexual disorders, the market can be classified into male hypogonadism therapy, prostate cancer therapy, erectile dysfunction therapy, premature ejaculation therapy, and other therapies. The prostate cancer therapy segment will be the fastest-growing segment owing to the high prevalence and increasing cases of cancer of prostate gland across the globe. The 2nd fastest-growing segment is male hypogonadism therapy.
Based on the type of product the male sexual therapeutics market can be segmented into drugs/ capsules, hormone injections, and creams & ointments. The capsules segment will be the largest and gain more traction during the forecast period. Addressing male sexual therapies in the form of capsules is more common than other product types in the market. Hence, these prescription-based capsules will capture a larger share than other product segments in the market.
Based on the source or platform of distribution channel, the market for sexual therapeutics in men can be segmented as hospital pharmacies, online pharmacies and retail pharmacies. The hospital pharmacies will have a lion’s share in the market while the online platform will be growing the fastest with the highest CAGR value during the forecast period of 2021 to 2026. Retail pharmacies is analyzed to be the second largest segment in terms of revenue growth in the male sexual therapeutics market.
As per the geographical analysis, the male sexual therapeutics market can be classified into North America (the United States, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa (Saudi Arabia, United Arab Emirates, and Rest of the Middle East & Africa) and Central South America (Brazil, Argentina, and Rest of Central and South America). With the rising prevalence and awareness of male sexual disorders, the market for North America is ought to be the largest from 2021 to 2026. Also, with many companies concentrating in launching latest drugs post FDA approval in US and Canada will help this region maintain its high position in the market. The reimbursement scenario associated with sexual wellbeing treatment is another factor supporting the market in North America. On the other hand, the market for Asia Pacific (APAC) will be growing the fastest with the highest CAGR value. The major driver for this is the rising geriatric or elderly male population who are susceptible to sexual disorders. Also, the rising awareness amongst younger generation regarding advanced and latest therapeutic plans related to sexual disorders will help maintain the high CAGR value for the Asian region in the market.
Intas Pharmaceuticals Ltd., Access Pharmaceuticals, Inc., ASKA Pharmaceutical Co., Trophogen, Inc., CordexPharma, Inc., ZydusCadila Healthcare Ltd., Bayer, Pantarhei Bioscience BV., Boston Scientific, Pfizer, Eli Lilly, Teva Pharmaceuticals, Vivus Meda Pharmaceuticals, and Sun Pharmaceutical among others are the players in the male sexual therapeutics market.
Please note: This is not an exhaustive list of companies profiled in the report.
Chapter 1 Methodology
1.1 Market Scope & Definitions
1.2 Estimates & Forecast Calculation
1.3 Historical Data Overview and Validation
1.4 Data Sources
1.4.1 Secondary
1.4.2 Primary
Chapter 2 Report Outlook
2.1 Male Sexual Therapeutics Industry Overview, 2019-2026
2.1.1 Industry Overview
2.1.2 Product Overview
2.1.3 Therapeutic Type Overview
2.1.4 Distribution Channel Overview
2.1.6 Regional Overview
Chapter 3 Male Sexual Therapeutics Market Trends
3.1 Market Segmentation
3.2 Industry Background, 2019-2026
3.3 Market Key Trends
3.3.1 Positive Trends
3.3.1.1 Rising number of male geriatric population susceptible to sexual disorders
3.3.1.2 Rising Prevalence of male hypogonadism and prostate cancer
3.3.2 Industry Challenges
3.3.2.1 Lack of awareness regarding sexual wellbeing in male in developing nations
3.4 Prospective Growth Scenario
3.4.1 Product Growth Scenario
3.4.2 Therapeutic Type Growth Scenario
3.4.3 Distribution Channel Growth Scenario
3.5 COVID-19 Influence over Industry Growth
3.6 Porter’s Analysis
3.7 PESTEL Analysis
3.8 Value Chain & Supply Chain Analysis
3.9 Regulatory Framework
3.9.1 North America
3.9.2 Europe
3.9.3 APAC
3.9.4 LATAM
3.9.5 MEA
3.10 Distribution Channel Overview
3.11 Market Share Analysis, 2020
3.11.1 Company Positioning Overview, 2020
Chapter 4 Male Sexual Therapeutics Market, By Product
4.1 Product Outlook
4.2 Capsules
4.2.1 Market Size, By Region, 2019-2026 (USD Million)
4.3 Hormone Injections
4.3.1 Market Size, By Region, 2019-2026 (USD Million)
4.4 Creams & Ointments
4.4.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 5 Male Sexual Therapeutics Market, By Therapeutic Type
5.1 Therapeutic Type Outlook
5.2 Male Hypogonadism Therapy
5.2.1 Market Size, By Region, 2019-2026 (USD Million)
5.3 Prostate Cancer Therapy
5.3.1 Market Size, By Region, 2019-2026 (USD Million)
5.4 Erectile Dysfunction Therapy
5.4.1 Market Size, By Region, 2019-2026 (USD Million)
5.5 Premature Ejaculation Therapy
5.5.1 Market Size, By Region, 2019-2026 (USD Million)
5.6 Others
5.6.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 6 Male Sexual Therapeutics Market, By Distribution Channel
6.1 Hospital Pharmacies
6.1.1 Market Size, By Region, 2019-2026 (USD Million)
6.2 Retail Pharmacies
6.2.1 Market Size, By Region, 2019-2026 (USD Million)
6.3 Online Pharmacies
6.3.1 Market Size, By Region, 2019-2026 (USD Million)
Chapter 8 Male Sexual Therapeutics Market, By Region
8.1 Regional outlook
8.2 North America
8.2.1 Market Size, By Country 2019-2026 (USD Million)
8.2.2 Market Size, By Product, 2019-2026 (USD Million)
8.2.3 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.2.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.2.6 U.S.
8.2.6.1 Market Size, By Product, 2019-2026 (USD Million)
8.2.4.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.2.4.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.2.7 Canada
8.2.7.1 Market Size, By Product, 2019-2026 (USD Million)
8.2.7.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.2.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.3 Europe
8.3.1 Market Size, By Country 2019-2026 (USD Million)
8.3.2 Market Size, By Product, 2019-2026 (USD Million)
8.3.3 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.3.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.3.6 Germany
8.3.6.1 Market Size, By Product, 2019-2026 (USD Million)
8.3.6.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.3.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.3.7 UK
8.3.7.1 Market Size, By Product, 2019-2026 (USD Million)
8.3.7.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.3.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.3.8 France
8.3.8.1 Market Size, By Product, 2019-2026 (USD Million)
8.3.8.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.3.8.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.3.9 Italy
8.3.9.1 Market Size, By Product, 2019-2026 (USD Million)
8.3.9.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.3.9.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.3.10 Spain
8.3.10.1 Market Size, By Product, 2019-2026 (USD Million)
8.3.10.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.3.10.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.3.11 Russia
8.3.11.1 Market Size, By Product, 2019-2026 (USD Million)
8.3.11.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.3.11.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.4 Asia Pacific
8.4.1 Market Size, By Country 2019-2026 (USD Million)
8.4.2 Market Size, By Product, 2019-2026 (USD Million)
8.4.3 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.4.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.4.6 China
8.4.6.1 Market Size, By Product, 2019-2026 (USD Million)
8.4.6.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.4.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.4.7 India
8.4.7.1 Market Size, By Product, 2019-2026 (USD Million)
8.4.7.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.4.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.4.8 Japan
8.4.8.1 Market Size, By Product, 2019-2026 (USD Million)
8.4.8.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.4.8.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.4.9 Australia
8.4.9.1 Market Size, By Product, 2019-2026 (USD Million)
8.4.9.2 Market size, By Therapeutic Type, 2019-2026 (USD Million)
8.4.9.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.4.10 South Korea
8.4.10.1 Market Size, By Product, 2019-2026 (USD Million)
8.4.10.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.4.10.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.5 Latin America
8.5.1 Market Size, By Country 2019-2026 (USD Million)
8.5.2 Market Size, By Product, 2019-2026 (USD Million)
8.5.3 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.5.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.5.6 Brazil
8.5.6.1 Market Size, By Product, 2019-2026 (USD Million)
8.5.6.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.5.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.5.7 Mexico
8.5.7.1 Market Size, By Product, 2019-2026 (USD Million)
8.5.7.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.5.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.5.8 Argentina
8.5.8.1 Market Size, By Product, 2019-2026 (USD Million)
8.5.8.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.5.8.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.6 MEA
8.6.1 Market Size, By Country 2019-2026 (USD Million)
8.6.2 Market Size, By Product, 2019-2026 (USD Million)
8.6.3 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.6.4 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.6.6 Saudi Arabia
8.6.6.1 Market Size, By Product, 2019-2026 (USD Million)
8.6.6.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.6.6.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.6.7 UAE
8.6.7.1 Market Size, By Product, 2019-2026 (USD Million)
8.6.7.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.6.7.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
8.6.8 South Africa
8.6.8.1 Market Size, By Product, 2019-2026 (USD Million)
8.6.8.2 Market Size, By Therapeutic Type, 2019-2026 (USD Million)
8.6.8.3 Market Size, By Distribution Channel, 2019-2026 (USD Million)
Chapter 9 Company Landscape
9.1 Competitive Analysis, 2020
9.2 Intas Pharmaceuticals Ltd.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Strategic Positioning
9.2.4 Info Graphic Analysis
9.3 Access Pharmaceuticals, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Strategic Positioning
9.3.4 Info Graphic Analysis
9.4 ASKA Pharmaceutical Co.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Strategic Positioning
9.4.4 Info Graphic Analysis
9.5 Trophogen, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Strategic Positioning
9.5.4 Info Graphic Analysis
9.6 CordexPharma, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Strategic Positioning
9.6.4 Info Graphic Analysis
9.7 ZydusCadila Healthcare Ltd.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Strategic Positioning
9.7.4 Info Graphic Analysis
9.8 Bayer
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Strategic Positioning
9.8.4 Info Graphic Analysis
9.9 Pfizer
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Strategic Positioning
9.9.4 Info Graphic Analysis
9.10 Eli Lilly
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Strategic Positioning
9.10.4 Info Graphic Analysis
9.11 Other Companies
9.11.1 Company Overview
9.11.2 Financial Analysis
9.11.3 Strategic Positioning
9.11.4 Info Graphic Analysis
The Global Male Sexual Therapeutics Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Male Sexual Therapeutics Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
Or view our licence options:
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?
OUR CLIENTS
